Verrica Pharmaceuticals (FRA:1NE) Current Accrued Expense : €5.16 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Current Accrued Expense?

Verrica Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2024 was €5.16 Mil.

Verrica Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2023 (€6.35 Mil) to Dec. 2023 (€4.42 Mil) but then increased from Dec. 2023 (€4.42 Mil) to Mar. 2024 (€5.16 Mil).

Verrica Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2021 (€1.42 Mil) to Dec. 2022 (€1.19 Mil) but then increased from Dec. 2022 (€1.19 Mil) to Dec. 2023 (€4.42 Mil).

Verrica Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Verrica Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Current Accrued Expense Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

0.76

1.46

1.42

1.19

4.42

Verrica Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															1.15	2.08	6.35	4.42	5.16

Verrica Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Verrica Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (FRA:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

VRCA:USA 1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines